Antigny Fabrice, Crottès David, Vandier Christophe, Capuano Véronique, Guéguinou Maxime
Université Paris-Saclay, INSERM, UMR_S 999, Hypertension Pulmonaire : Physiopathologie and Innovation Thérapeutique (HPPIT), AP-HP, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), ERN-LUNG, FHU André Cournand, Le Plessis Robinson, France.
Université de Tours, INSERM Unité Mixte de Recherche (UMR) 1069 N2COx Niche, Nutrition, Cancer, et Métabolisme Oxydatif, Tours, France.
Trends Mol Med. 2025 Apr 1. doi: 10.1016/j.molmed.2025.03.002.
Pulmonary arterial hypertension (PAH) and cancer may appear to be unrelated at first, but there is increasing evidence that they share many characteristics and complexities. Pulmonary vascular cells in PAH resemble cancer cells in that they display abnormal growth patterns, resistance to cell death, metabolic changes, and channelopathies. These similarities open new possibilities for researchers and clinicians to apply cancer treatment strategies to PAH and possibly reverse the condition. This review explores the complex parallels between PAH and cancer, and emphasizes their similar channelopathy-like features at the molecular, cellular, and clinical levels. We also discuss the potential implications of these similarities for developing new treatments.
肺动脉高压（PAH）与癌症起初可能看似并无关联，但越来越多的证据表明，它们具有许多共同特征和复杂性。PAH中的肺血管细胞与癌细胞相似，因为它们呈现出异常的生长模式、对细胞死亡的抗性、代谢变化以及离子通道病。这些相似之处为研究人员和临床医生将癌症治疗策略应用于PAH并可能逆转病情开辟了新的可能性。本综述探讨了PAH与癌症之间的复杂相似之处，并强调了它们在分子、细胞和临床水平上类似离子通道病的特征。我们还讨论了这些相似性对开发新疗法的潜在影响。
